You are here

Article Text

Article menu

This article has a correction. Please see:

Download PDFPDF

Chest clinic
Audit, research and guideline update
Obtaining real-world evidence: the Salford Lung Study
  1. John P New1,
  2. Nawar Diar Bakerly1,
  3. David Leather2,
  4. Ashley Woodcock3
  1. 1Salford Royal NHS Foundation Trust, Salford, UK
  2. 2GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex, UK
  3. 3Institute of Inflammation and Repair, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK
  1. Correspondence to Professor Ashley Woodcock, Institute of Inflammation and Repair, 2nd Floor Education and Research Centre, University Hospital of South Manchester NHS Foundation Trust, Southmoor Road, Manchester M23 9LT, UK; ashley.woodcock{at}manchester.ac.uk

Abstract

We need to assess clinical treatments in real-life settings outside of randomised controlled trials (RCTs). Pragmatic RCT (pRCT) data can supplement RCTs by providing effectiveness information to support healthcare decisions. Electronic health records can facilitate concurrent safety monitoring and data collection without direct patient contact for large randomised study populations in pRCTs. The Salford Lung Study is the world's first phase III pRCT in asthma and chronic obstructive pulmonary disease (COPD), which aims to randomise over 7000 patients. This paper describes the hurdles overcome and the enormous effort and resource required to establish this comparative effectiveness study of a prelicence intervention.

GlaxoSmithKline protocol HZC115151

Asthma study clinicaltrials.gov registration NCT01706198

COPD study clinicaltrials.gov registration NCT01551758

  • Asthma
  • COPD Exacerbations

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

http://dx.doi.org/10.1136/thoraxjnl-2014-205259

Statistics from Altmetric.com

    View Full Text

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

    Linked Articles

    • Airwaves
      Highlights from this issue
      Andrew Bush Ian Pavord
      Thorax 2014; 69 i-i Published Online First: 11 Nov 2014. doi: 10.1136/thoraxjnl-2014-206460
    • Correction
      Correction
      BMJ Publishing Group Ltd and British Thoracic Society
      Thorax 2015; 70 1008-1008 Published Online First: 13 Sep 2015. doi: 10.1136/thoraxjnl-2014-205259corr1